What were the net revenues for Quest Diagnostics (NYSE:DGX) in the second quarter of 2026?

Quest Diagnostics (NYSE:DGX) reported second-quarter 2026 net revenues of $3.04 billion. This represents a 10.2 percent increase year over year, driven largely by 10.0 percent organic revenue growth.

How much did Quest Diagnostics (NYSE:DGX) earn per share in Q2 2026?

The company reported adjusted diluted earnings per share of $3.12, a 19.1 percent increase from the prior year. Reported diluted EPS was $2.84, up 15.0 percent.

What drove the revenue growth for Quest Diagnostics during the quarter?

Revenue growth was fueled by strong organic demand, including a 13.1 percent increase in requisition volume and a 10.3 percent rise in Diagnostic Information Services revenues.

How much cash flow did Quest Diagnostics generate in Q2 2026?

Quest Diagnostics generated $597 million in operating cash flow during the second quarter, representing a 9.7 percent increase year over year.

What is the updated full-year 2026 guidance for Quest Diagnostics?

Management raised its full-year 2026 guidance, now expecting net revenues between $11.95 billion and $12.05 billion. The company projects adjusted diluted EPS of $11.05 to $11.25 and increased its expected cash from operations to approximately $1.80 billion.

Image for illustrative purposes only. Not a real photo.

Quest Diagnostics revenue expands 10.2% to $3.04 billion

Written by Jon CuthbertPublished Jul 23, 2026, 12:18 PM

Quest Diagnostics reported second-quarter revenue of $3.04 billion, up 10.2%, with organic revenue growth of 10%.
Adjusted EPS increased 19.1% to $3.12, while Quest Diagnostics shares rose 1.7% to $209.83 in premarket trading.
The company raised its full-year revenue, earnings and operating-cash-flow forecasts following the quarterly results.

Quest Diagnostics (NYSE:DGX) reported second-quarter revenue of $3.04 billion, up 10.2%, as diagnostic-testing volumes increased across its customer channels.

Revenue rose from $2.76 billion and exceeded the $2.97 billion analyst consensus, while adjusted EPS of $3.12 topped the $2.82 estimate.

Requisition volume rose 13.1%, revenue per requisition fell 2.8%, and operating cash flow increased 9.7% to $597 million.

Following the announcement, Quest Diagnostics's share price was up 1.7% at $209.83 in premarket trading.

Diagnostic Information Services revenue increased 10.3% to $2.98 billion, supported by physician, hospital, consumer and advanced-diagnostics demand.

Looking ahead, Quest Diagnostics raised its 2026 revenue forecast to $11.95 billion–$12.05 billion and adjusted EPS guidance to $11.05–$11.25.

Quest Diagnostics revenue expands 10.2% to $3.04 billion

Frequently asked questions

Assets related to this article